AVA6000 in advanced solid tumors incl. soft tissue sarcomas

 

Trial name: ADC AVA6000 in Advanced Solid Tumors
Agents: AVA6000
Phase I
Status Recruiting
Sponsor Avacta Life Sciences Ltd

 

This phase I study evaluates the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000 in patients with locally advanced and/or metastatic solid tumours incl. soft tissue sarcomas.

Further information can be found on clinicaltrials.gov.

 

WHO is the trial for?
  • Adult patients with confirmed diagnosis of locally advanced or metastatic soft tissue sarcoma that cannot be operated
  • Patients whose tumor as progressed after or are intolerant to standard therapy
  • Overall health status has to be good (ECOG below or equal to 1)

Excluded are patients who have received a dose of doxorubicin exceeding a certain threshold.

WHAT is the key question that this trial is attempting to answer?

 This study aims to determine the best dose of a new treatment, AVA6000, and to check its safety and early signs of effectiveness in treating soft tissue sarcoma (STS) and other types of cancer.

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease.

The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 The study is open for recruitment.

WHERE is the trial available?

 The trial is open in the UK and the US. Please check for current information here.

STUDY DESIGN: What does the study look like?

 This is a phase 1 trial to find out how safe and effective the treatment is for patients with advanced cancers incl. soft tissue sarcomas.

The study has two parts:

  • Phase 1a: Patients receive increasing doses of AVA6000 to determine the safest and most effective dose.
  • Phase 1b: More patients with specific cancers will receive the chosen dose to see how well it works.

The goal is to learn about the safety and effectiveness of AVA6000 for treating cancer incl. soft tissue sarcomas.

HOW do I get more information?

 Patient organizations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken